Molecular classification of breast tumors: toward improved diagnostics and treatments.

Recent advances in gene expression profiling and other "omics" technologies have revolutionized cancer research and hold the potential of also revolutionizing clinical practice. These high-throughout approaches have radically changed our ability to study cells and tissues in a more comprehensive way. Combined with advanced bioinformatics and the possibility to simulate biological processes in computers, this field of "systems biology" allows us to study the organism as a whole entity. This chapter describes the molecular classification and characterization of breast tumors into distinct subtypes by using DNA microarrays and discusses the statistical relationships of the subgroups with clinical features of the disease.

[1]  Ash A. Alizadeh,et al.  Genome-wide analysis of DNA copy-number changes using cDNA microarrays , 1999, Nature Genetics.

[2]  T. Aas,et al.  Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer. , 2001, Cancer research.

[3]  Wei Wang,et al.  A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. , 2004, Cancer cell.

[4]  Carole L Yauk,et al.  Comprehensive comparison of six microarray technologies. , 2004, Nucleic acids research.

[5]  Yudong D. He,et al.  A Gene-Expression Signature as a Predictor of Survival in Breast Cancer , 2002 .

[6]  E. Rosen,et al.  BRCA1 Inhibits Membrane Estrogen and Growth Factor Receptor Signaling to Cell Proliferation in Breast Cancer , 2004, Molecular and Cellular Biology.

[7]  Shinzaburo Noguchi,et al.  Prediction of docetaxel response in human breast cancer by gene expression profiling. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  Tatsuhiko Tsunoda,et al.  Expression profiling to predict postoperative prognosis for estrogen receptor‐negative breast cancers by analysis of 25,344 genes on a cDNA microarray , 2004, Cancer science.

[9]  A. Levine,et al.  Surfing the p53 network , 2000, Nature.

[10]  Daniel Birnbaum,et al.  Gene expression profiling identifies molecular subtypes of inflammatory breast cancer. , 2005, Cancer research.

[11]  Puay Hoon Tan,et al.  Conservation of Breast Cancer Molecular Subtypes and Transcriptional Patterns of Tumor Progression Across Distinct Ethnic Populations , 2004, Clinical Cancer Research.

[12]  R. Tibshirani,et al.  Repeated observation of breast tumor subtypes in independent gene expression data sets , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[13]  J Piper,et al.  Detection and mapping of amplified DNA sequences in breast cancer by comparative genomic hybridization. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[14]  Christian A. Rees,et al.  Systematic variation in gene expression patterns in human cancer cell lines , 2000, Nature Genetics.

[15]  Yudong D. He,et al.  Gene expression profiling predicts clinical outcome of breast cancer , 2002, Nature.

[16]  R. Vossen,et al.  Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer. , 2000, Cancer research.

[17]  Annuska M Glas,et al.  Gene expression profiles of primary breast tumors maintained in distant metastases , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[18]  J Chang-Claude,et al.  Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. , 1998, American journal of human genetics.

[19]  R. Tibshirani,et al.  Significance analysis of microarrays applied to the ionizing radiation response , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[20]  Therese Sørlie,et al.  Molecular portraits of breast cancer: tumour subtypes as distinct disease entities. , 2004, European journal of cancer.

[21]  Julian Peto,et al.  Prediction of BRCA1 Status in Patients with Breast Cancer Using Estrogen Receptor and Basal Phenotype , 2005, Clinical Cancer Research.

[22]  Maurice P H M Jansen,et al.  Molecular classification of tamoxifen-resistant breast carcinomas by gene expression profiling. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  T. Sørlie,et al.  Mutation screening of the TP53 gene by temporal temperature gradient gel electrophoresis. , 2005, Methods in molecular biology.

[24]  Trevor Hastie,et al.  Gene expression patterns in ovarian carcinomas. , 2003, Molecular biology of the cell.

[25]  C. Ball,et al.  Identification of genes periodically expressed in the human cell cycle and their expression in tumors. , 2002, Molecular biology of the cell.

[26]  F. Wright,et al.  Gene expression profiling of isogenic cells with different TP53 gene dosage reveals numerous genes that are affected by TP53 dosage and identifies CSPG2 as a direct target of p53 , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[27]  Gideon Rechavi,et al.  DNA microarray analysis of genes involved in p53 mediated apoptosis: activation of Apaf-1 , 2001, Oncogene.

[28]  M. Ringnér,et al.  Impact of DNA amplification on gene expression patterns in breast cancer. , 2002, Cancer research.

[29]  John Quackenbush,et al.  Computational genetics: Computational analysis of microarray data , 2001, Nature Reviews Genetics.

[30]  M. Fernö,et al.  "Good Old" clinical markers have similar power in breast cancer prognosis as microarray gene expression profilers. , 2004, European journal of cancer.

[31]  T. Sørlie,et al.  Genomics in breast cancer—therapeutic implications , 2005, Nature Clinical Practice Oncology.

[32]  Syed Mohsin,et al.  Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer , 2003, The Lancet.

[33]  Y. Chen,et al.  Comparative genomic hybridization analysis of 38 breast cancer cell lines: a basis for interpreting complementary DNA microarray data. , 2000, Cancer research.

[34]  P. Hainaut,et al.  TP53: a key gene in human cancer. , 2002, Biochimie.

[35]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[36]  K. Vousden,et al.  Activation and activities of the p53 tumour suppressor protein , 2001, British Journal of Cancer.

[37]  M. Ringnér,et al.  Classification and diagnostic prediction of cancers using gene expression profiling and artificial neural networks , 2001, Nature Medicine.

[38]  Howard Y. Chang,et al.  Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[39]  W. McGuire,et al.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.

[40]  John Quackenbush,et al.  Open source software for the analysis of microarray data. , 2003, BioTechniques.

[41]  Barbara L. Smith,et al.  Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  E. Hovig,et al.  TP53 mutations and breast cancer prognosis: Particularly poor survival rates for cases with mutations in the zinc‐binding domains , 1995, Genes, chromosomes & cancer.

[43]  R. Tibshirani,et al.  Diagnosis of multiple cancer types by shrunken centroids of gene expression , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[44]  A. Lazaris,et al.  PROGNOSTIC SIGNIFICANCE OF THE CO‐EXPRESSION OF p53 AND c‐erbB‐2 PROTEINS IN BREAST CANCER , 1996, The Journal of pathology.

[45]  A. Sasco.  Breast Cancer and the Environment , 2003, Hormone Research in Paediatrics.

[46]  Mike Clarke,et al.  Tamoxifen for early breast cancer: an overview of the randomised trials , 1998, The Lancet.

[47]  Jürgen Geisler,et al.  TP53 gene mutations predict the response to neoadjuvant treatment with 5-fluorouracil and mitomycin in locally advanced breast cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[48]  Yusuke Nakamura,et al.  Gene expression patterns as marker for 5-year postoperative prognosis of primary breast cancers , 2004, Journal of Cancer Research and Clinical Oncology.

[49]  Christian A. Rees,et al.  Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[50]  E. Dougherty,et al.  Gene-expression profiles in hereditary breast cancer. , 2001, The New England journal of medicine.

[51]  T. Aas,et al.  Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients , 1996, Nature Medicine.

[52]  Eytan Domany,et al.  Outcome signature genes in breast cancer: is there a unique set? , 2004, Breast Cancer Research.

[53]  Duccio Cavalieri,et al.  Standards for Microarray Data , 2002, Science.

[54]  Ronald W. Davis,et al.  Quantitative Monitoring of Gene Expression Patterns with a Complementary DNA Microarray , 1995, Science.

[55]  J Isola,et al.  Molecular cytogenetics of primary breast cancer by CGH , 1998, Genes, chromosomes & cancer.

[56]  R. Tibshirani,et al.  Gene expression profiling identifies clinically relevant subtypes of prostate cancer. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[57]  Philip M. Long,et al.  Breast cancer classification and prognosis based on gene expression profiles from a population-based study , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[58]  David Botstein,et al.  Different gene expression patterns in invasive lobular and ductal carcinomas of the breast. , 2004, Molecular biology of the cell.

[59]  D. Botstein,et al.  Gene expression patterns in human liver cancers. , 2002, Molecular biology of the cell.

[60]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[61]  L. Holmberg,et al.  Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy , 1995, Nature Medicine.

[62]  David Botstein,et al.  BMC Genomics BioMed Central Methodology article Universal Reference RNA as a standard for microarray experiments , 2004 .

[63]  Christine Solbach,et al.  Identification of high risk breast-cancer patients by gene expression profiling , 2002, The Lancet.

[64]  M. West,et al.  Gene expression predictors of breast cancer outcomes , 2003, The Lancet.

[65]  Christian A. Rees,et al.  Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[66]  D. Botstein,et al.  Cluster analysis and display of genome-wide expression patterns. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[67]  J. Stec,et al.  Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[68]  M. Erdos,et al.  BRCA1 inhibition of estrogen receptor signaling in transfected cells. , 1999, Science.

[69]  E. Lander,et al.  A molecular signature of metastasis in primary solid tumors , 2003, Nature Genetics.

[70]  D Haussler,et al.  Knowledge-based analysis of microarray gene expression data by using support vector machines. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[71]  A. Chinnaiyan,et al.  Integrative analysis of the cancer transcriptome , 2005, Nature Genetics.

[72]  David Botstein,et al.  RERG Is a Novel ras-related, Estrogen-regulated and Growth-inhibitory Gene in Breast Cancer* , 2001, The Journal of Biological Chemistry.

[73]  G. Giles,et al.  Distinct molecular pathogeneses of early-onset breast cancers in BRCA1 and BRCA2 mutation carriers: a population-based study. , 1999, Cancer research.

[74]  Sridhar Ramaswamy,et al.  Loss of Heterozygosity and Its Correlation with Expression Profiles in Subclasses of Invasive Breast Cancers , 2004, Cancer Research.